Search Results - "Fuerst, Joy"

MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate by Beshore, Douglas C., N. Di Marco, Christina, Chang, Ronald K., Greshock, Thomas J., Ma, Lei, Wittmann, Marion, Seager, Matthew A., Koeplinger, Kenneth A., Thompson, Charles D., Fuerst, Joy, Hartman, George D., Bilodeau, Mark T., Ray, William J., Kuduk, Scott D.

“…Identification of ligands that selectively activate the M1 muscarinic signaling pathway has been sought for decades to treat a range of neurological and…”
Get full text

Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia by Raheem, Izzat T., Schreier, John D., Fuerst, Joy, Gantert, Liza, Hostetler, Eric D., Huszar, Sarah, Joshi, Aniket, Kandebo, Monika, Kim, Somang H., Li, Jing, Ma, Bennett, McGaughey, Georgia, Sharma, Sujata, Shipe, William D., Uslaner, Jason, Vandeveer, George H., Yan, Youwei, Renger, John J., Smith, Sean M., Coleman, Paul J., Cox, Christopher D.

“…[Display omitted] Herein, we present the identification of a novel class of pyrazolopyrimidine phosphodiesterase 10A (PDE10A) inhibitors. Beginning with a lead…”
Get full text

Designing an ADME liquid formulation with matching exposures to an amorphous dosage form by Xi, Hanmi, Yang, Zhen, Tatavarti, Aditya, Xu, Wei, Fuerst, Joy, Ormes, James

“…[Display omitted] Amorphous Solid Dispersion (ASD) based formulations have been frequently used to improve the bioavailability of poorly water soluble drugs,…”
Get full text

Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia by Layton, Mark E., Kern, Jeffrey C., Hartingh, Timothy J., Shipe, William D., Raheem, Izzat, Kandebo, Monika, Hayes, Robert P., Huszar, Sarah, Eddins, Donnie, Ma, Bennett, Fuerst, Joy, Wollenberg, Gordon K., Li, Jing, Fritzen, Jeff, McGaughey, Georgia B., Uslaner, Jason M., Smith, Sean M., Coleman, Paul J., Cox, Christopher D.

“…PDE10A is an important regulator of striatal signaling that, when inhibited, can normalize dysfunctional activity. Given the involvement of dysfunctional…”
Get full text

MK-7622: A First-in-Class M 1 Positive Allosteric Modulator Development Candidate by Beshore, Douglas C, N Di Marco, Christina, Chang, Ronald K, Greshock, Thomas J, Ma, Lei, Wittmann, Marion, Seager, Matthew A, Koeplinger, Kenneth A, Thompson, Charles D, Fuerst, Joy, Hartman, George D, Bilodeau, Mark T, Ray, William J, Kuduk, Scott D

“…Identification of ligands that selectively activate the M muscarinic signaling pathway has been sought for decades to treat a range of neurological and…”
Get full text

Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia by Raheem, Izzat T., Breslin, Michael J., Fandozzi, Christine, Fuerst, Joy, Hill, Nicole, Huszar, Sarah, Kandebo, Monika, Kim, Somang H., Ma, Bennett, McGaughey, Georgia, Renger, John J., Schreier, John D., Sharma, Sujata, Smith, Sean, Uslaner, Jason, Yan, Youwei, Coleman, Paul J., Cox, Christopher D.

“…We describe the discovery of potent and orally bioavailable tetrahydropyridopyrimidine inhibitors of phosphodiesterase 10A by systematic optimization of a…”
Get full text